Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression.
J Chemother
; 17(3): 321-6, 2005 Jun.
Article
en En
| MEDLINE
| ID: mdl-16038527
ABSTRACT
O6-Methylguanine-DNA-Methyltransferase (MGMT) is a DNA repair protein considered to be a chemosensitivity predictor. We evaluated the immunohistochemical MGMT expression in 28 consecutive oligodendroglial tumors (21 oligodendrogliomas, 5 mixed oligoastrocytomas, and 2 glioblastomas with prominent oligodendroglial features; 13 treated with CCNU) and compared it with that of 13 glioblastomas. Twenty-six (93%) oligodendroglial tumors were MGMT-negative, 2 (7%) were MGMT-positive. Twelve (92%) patients treated with CCNU had MGMT-negative lesions and their median survival was 73 months; 1 patient had an MGMT-positive oligodendroglioma and is alive at 28 months. Three (23%) glioblastomas were MGMT-negative and 10 (77%) MGMT-positive. The lower MGMT expression in oligodendroglial tumors compared to glioblastomas (P < 0.05), which have different chemosensitivity, suggests a possible role of MGMT in the determination of chemoresistance. Nevertheless, the heterogeneous outcome of our MGMT-negative oligodendroglial tumors treated with CCNU, indicates that MGMT expression alone is insufficient to predict the response to alkylating drugs, presumably because of the numerous mechanisms involved.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Oligodendroglioma
/
Neoplasias Encefálicas
/
Glioblastoma
/
O(6)-Metilguanina-ADN Metiltransferasa
/
Perfilación de la Expresión Génica
/
Reparación del ADN
/
Antineoplásicos
/
Compuestos de Nitrosourea
Tipo de estudio:
Prognostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2005
Tipo del documento:
Article